Tatva Chintan Pharma accepts Ajay Rawat resignation as R&D head

1 min read     Updated on 19 Aug 2026, 08:07 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Tatva Chintan Pharma Chem Ltd announced the acceptance of Mr. Ajay Rawat’s resignation as Assistant Vice President – Research and Development. Effective November 13, 2026, Mr. Rawat will cease to be part of the senior management team after submitting his resignation on August 14, 2026. The move was disclosed under Regulation 30 of SEBI Listing Regulations.

powered bylight_fuzz_icon
48695850

*this image is generated using AI for illustrative purposes only.

Tatva Chintan Pharma Chem Limited has accepted the resignation of Mr. Ajay Rawat, who served as Assistant Vice President – Research and Development. The company disclosed that Mr. Rawat submitted his resignation letter on August 14, 2026, citing personal career opportunities as the reason for his departure.

The management formally accepted the resignation on August 19, 2026. Mr. Rawat’s exit will become effective from the close of business hours on November 13, 2026. During this transition period, he will continue to perform his duties as a Senior Management Personnel of the company.

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, which was issued on July 11, 2023, and last updated on January 30, 2026.

Particulars Details
Resigning Executive Mr. Ajay Rawat
Designation Assistant Vice President – Research and Development
Resignation Date August 14, 2026
Acceptance Date August 19, 2026
Effective Date November 13, 2026

The complete disclosure, including Annexure A and a copy of the resignation letter, is available on the company’s website at www.tatvachintan.com . Ishwar Nayi, Company Secretary and Compliance Officer, signed the communication to the stock exchanges.

Historical Stock Returns for Tatva Chintan Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.31%-7.71%-3.85%+37.35%+52.66%-25.19%

How will Tatva Chintan Pharma Chem plan to fill the Assistant Vice President – R&D role to ensure continuity in its pipeline development?

Does Mr. Rawat's departure signal a broader shift in the company's research strategy or potential restructuring within the R&D department?

What impact might this leadership change have on the timeline for upcoming clinical trials or product launches currently under his supervision?

Tatva Chintan Pharma sets Sept 10 deadline for dividend tax docs

2 min read     Updated on 11 Aug 2026, 07:24 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Tatva Chintan Pharma Chem Limited requires shareholders to submit tax documents by September 10, 2026, for its ₹2.00 per share final dividend. Residents face 10% TDS unless exempt, while non-residents pay 20% unless DTAA benefits are claimed with proper documentation. Non-compliance results in a 20% TDS rate.

powered bylight_fuzz_icon
48002058

*this image is generated using AI for illustrative purposes only.

Tatva Chintan Pharma Chem Limited has issued an intimation to shareholders regarding the Tax Deduction at Source (TDS) on its final dividend for FY26, setting a strict deadline of September 10, 2026, for document submission. The Board of Directors, in a meeting held on May 16, 2026, recommended a final dividend of ₹2.00 per equity share (face value ₹10), representing a 20% payout. This dividend is subject to shareholder approval at the 30th Annual General Meeting (AGM). Under the Income-tax Act, 2025, dividend income is taxable in the hands of shareholders, requiring the company to deduct tax at source before payment.

The company has outlined specific TDS rates based on shareholder category and documentation status. For resident individual shareholders, no TDS will be deducted if the aggregate dividend payable during the tax year does not exceed ₹10,000. Other resident shareholders with valid PAN cards are subject to a 10% TDS rate. However, shareholders who fail to provide a valid PAN, have an unlinked PAN-Aadhaar combination, or are classified as specified persons under the income tax portal will face a higher TDS rate of 20% under Section 397(2)(b)(i) of the Act. Resident entities such as insurance companies, mutual funds, and Alternative Investment Funds (AIFs) may claim NIL or lower withholding tax by submitting self-declarations and relevant registration documents.

Non-resident shareholders, including Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs), face a standard withholding tax rate of 20%, plus applicable surcharge and cess. To avail benefits under the Double Tax Avoidance Agreement (DTAA), non-residents must submit a Tax Residency Certificate (TRC), Form 41 via the income tax portal, and a self-declaration confirming no Permanent Establishment in India. The application of beneficial DTAA rates is contingent upon the completeness and satisfactory review of these documents by the company. In the absence of valid documentation, the standard higher rate will apply.

Key Compliance Deadlines and Requirements

Shareholders must update their records with their Depository Participants (for demat holdings) or the Registrar and Share Transfer Agent, MUFG Intime India Private Limited (for physical holdings). The following table summarizes the critical compliance actions:

Action Required Deadline Consequence of Non-Compliance
Submit PAN/Residency Docs September 10, 2026 Higher TDS rate (20%) applied
Link PAN with Aadhaar Before Record Date PAN deemed invalid; 20% TDS
Furnish Rule 203 Declaration September 30, 2026 Tax credit not adjusted correctly

The company emphasized that no communication regarding tax determination or deduction will be entertained after September 10, 2026. Shareholders holding shares under multiple accounts with a single PAN will be subject to the highest applicable TDS rate across all their holdings. Additionally, clearing members must ensure shares are transferred to respective shareholder accounts by the record date to facilitate direct dividend credit.

What the Numbers Show

The mandatory shift to shareholder-level taxation, enforced through strict TDS mechanisms, highlights the regulatory emphasis on compliance under the Income-tax Act, 2025. The imposition of a 20% penalty rate for non-compliance—specifically for unlinked PAN-Aadhaar details or missing documentation—serves as a significant deterrent against administrative lapses. For institutional investors, the requirement to file Form 41 digitally and provide TRCs adds a layer of procedural complexity that must be managed well before the payment date to avoid cash flow impacts from excess withholding.

Historical Stock Returns for Tatva Chintan Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.31%-7.71%-3.85%+37.35%+52.66%-25.19%

How might the strict September 2026 TDS deadline impact the short-term liquidity and trading volume of Tatva Chintan Pharma shares among retail investors?

Will the increased compliance burden for non-resident investors under the new Income-tax Act provisions affect FII and FPI participation in Indian mid-cap pharmaceutical stocks?

Could the 20% penalty TDS rate for unlinked PAN-Aadhaar accounts lead to a surge in last-minute administrative requests, potentially straining registrar systems before the record date?

More News on Tatva Chintan Pharma

1 Year Returns:+52.66%